Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.

Pediatric nephrology (Berlin, Germany) - 1 Aug 2013

Gilbert Rodney D, Fowler Darren J, Angus Elizabeth, Hardy Stephen A, Stanley Louise, Goodship Timothy H

Abstract excerpt

BACKGROUND: Atypical haemolytic uraemic syndrome (aHUS) is caused by dysregulated complement activation. A humanised anti-C5 monoclonal antibody has recently become available for treatment of this condition CASE-DIAGNOSIS/TREATMENT: We present the first description of an infant with an activating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Atypical Hemolytic Uremic Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Biopsy

Share to Complement Factor B

Share to Hemolytic-Uremic Syndrome

Share to Immunologic Factors

Share to L-Lactate Dehydrogenase

Source

Identifiers

PMID: 23624872
DOI: 10.1007/s00467-013-2492-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23624872-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B.PMID 23624872Read ↗

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)Semantic proximity Read ↗

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.Semantic proximity Read ↗

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysisSemantic proximity Read ↗

Eculizumab for atypical haemolytic uraemic syndrome: what next?Semantic proximity Read ↗

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.Semantic proximity Read ↗

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practiceSemantic proximity Read ↗

aHUS caused by complement dysregulation: new therapies on the horizon.Semantic proximity Read ↗

Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeSemantic proximity Read ↗

Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumabSemantic proximity Read ↗

Atypical HUS: time to take stock of current guidelines and outcome measures?Semantic proximity Read ↗

Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing managementSemantic proximity Read ↗

Eculizumab and drug-induced haemolytic-uraemic syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.